Ketamine One says subsidiary expanding with new veteran-focused clinics in Canada
The four clinics will be located in the Comox Valley, Ottawa, Halifax, and Surrey
Sector
Health
1090 stories · page 42 of 55
Braxia Scientific announces Canada's first multiple-dose psilocybin clinical trial for treatment-resistant depression
The study will demonstrate that it can effectively conduct a randomized controlled trial using psychedelic-assisted therapy, enabling it to build the infrastructure for future studies and future clinical care
MMJ Group invests US$1 million in US digital health and pathology company Brainworks
“The investment in Brainworks demonstrates MMJ’s expertise to secure a private negotiated investment in unlisted businesses which are not generally available to Australian retail and institutional investors,” says chairman.
ASX falls, but makes up some losses ... while one small cap is up over 40%
MGC Pharmaceuticals Ltd has been a huge winner today, up 43.59%. MXC has signed a landmark deal with an American drug distributor worth a minimum US$24 million over the next three years.
Pathway Health excited about growth opportunities ahead as it reports second quarter results
The company said it ended the period to June 30 this year with $6.4 million (m) in cash
NA Proactive news snapshot: Zynerba Pharmaceuticals, Gevo, Canada Silver Cobalt Works, ESE Entertainment, DGTL Holdings UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Ketamine One establishes Medical Advisory Board
The company expects to add other members to the foundational board in due course, as appropriate
Revive Therapeutics expands clinical stage pipeline with Ganoderma lucidum license deal
The agreement was struck with Puerto Rico Science Technology and Research Trust (PRSTRT), representing Universidad Central del Caribe (UCC) and St. Jude Children’s Research Hospital (St. Jude)
Binovi Technologies provides first response to unsolicited bid for the company by Captiva Verde Wellness
The company said it has been informed by the principals that Captiva Verde intends to launch a bid to acquire the company for 7 cents per share, a 75% premium over Binovi's closing price on Friday, August 14
NA Proactive news snapshot: Alpine 4 Holdings, EVmo, Recruiter.com Group, Belmont Resources, HempFusion Wellness UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Ketamine One Capital says its wholly-owned contract research organization, KGK Science Inc recently secured a significant amount of new business
KGK has signed four new contracts with third-party clinical research and regulatory service clients and has also been formally selected to conduct the clinical trials for four other parties, the contracts of which are currently being negoti
Noble Capital slaps Outperform rating on PsyBio Therapeutics as it initiates coverage with a $2 price target
Noble's analysts noted that the firm’s proprietary manufacturing process for making psilocybin as well as related psychedelics could increase efficacy at lower doses
PharmaDrug and the Terasaki Institute to develop ocular delivery platform for DMT to treat eye diseases
The two groups will develop the platform to transmit tryptamine-based pharmaceuticals such as DMT to treat eye diseases like glaucoma, the second-leading cause of blindness in the world
Ketamine One to use virtual reality technology in psychedelic treatments
It is partnering with OVR Tech to provide its INHALE Wellness Platform, which combines the benefits of mindfulness, breathwork, and meditation with the next generation of aromatherapy
Empower Clinics acquires Canadian diabetes leader Medicare
The company said it will be immediately applying for FDA approval and expanding to the US market to dramatically enhance the business model of MediSure and maximizing its potential
Braxia Scientific reveals cash balance of C$11.1M after a busy 4Q
It expects to add to its clinic network in the coming year and continue conducting clinical trials – most of which will be funded by third parties
Binovi Technologies continues to execute on its growth strategy as it files its financial statements for the twelve months ended February 28, 2021
While the impact from the coronavirus (COVID-19) pandemic did result in longer sales cycles than usual, strong momentum and interest in the company's offering resulted in revenue growth of approximately 5%
Braxia Scientific awarded C$918,000 to study effectiveness of ketamine and cognitive behavioural therapy combo in reducing suicidality
The funding will go towards studying the effectiveness of intravenous ketamine in combination with internet-based CBT to reduce suicidality in people living with depression
Ketamine One makes moves on the research front to advance its work on psychedelics and nutraceuticals
The company's subsidiary KGK Science has applied for a narcotics license and completed pre-qualification audits ahead of clinical trials
SpectrumX starts work on a facility that will produce a pioneering, safe non-alcohol hand sanitiser
It has signed a lease in Knutsford, Cheshire, from where it will manufacture Spectricept and a “range of other innovative pharmaceutical and cosmetic products”